Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 --0%
EPS Growth %: -133.3%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
CAN, UNFI, SUNB, More
EPS Growth %: -133.3%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Prabhudas Lilladher Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
